Full-Time

Field Reimbursement Manager

Market Access, Mid-Atlantic Region

Updated on 9/11/2026

GE Healthcare

GE Healthcare

1-10 employees

Imaging, monitoring, and healthcare IT solutions

Compensation Overview

$132k - $198k/yr

+ Performance-based incentive compensation + Cash bonus(es) + Long-term incentives

No H1B Sponsorship

Remote in USA

Remote

Remote within the United States, with travel up to 40% required. Must live within the Mid-Atlantic territory.

Bachelor's

Category
Customer Experience & Support (1)
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to GE Healthcare

See people who can refer or advise you

Requirements
  • A bachelor's degree or equivalent is required.
  • At least 5 years of experience in the United States healthcare, medical device, or pharmaceutical sector is required.
  • At least 3 years of United States Field Reimbursement Manager experience is required.
  • Knowledge of and experience with medical benefit reimbursement and payment mechanisms, including medical coding, claims, and billing processes, are required.
  • Comprehensive knowledge of government coverage, including Medicare and Medicaid, and commercial coverage and reimbursement dynamics is required.
  • Familiarity with provider office and hospital outpatient department reimbursement, regulations, customers, and account-based planning is required.
  • Knowledge of the radiology authorization process, including HCPCS, CPT, and ICD-10 codes and associated regulations, is required.
  • Experience working with a HUB or reimbursement call center is required.
  • The ability to establish close collaboration with strategic partners and peers and lead collaborative initiatives is required.
  • Problem-solving and decision-making skills, including the ability to suggest alternatives and solutions, are required.
  • A strong customer focus and the ability to build relationships, identify and resolve access challenges, and manage complex projects are required.
  • The ability to operate independently and successfully as a leader in a matrix environment is required.
  • Strong organization, strategic thinking, and verbal and written presentation skills are required.
  • The ability to travel to connect with customers and field sales teams is required.
  • Demonstrated competence with customer relationship management systems, PowerPoint, Excel, and Word is required.
  • The candidate must live within the Mid-Atlantic territory.
  • The candidate must be legally authorized to work in the United States.
Responsibilities
  • Serve as the subject matter expert on reimbursement support programs, payer claim processes, and access issue resolution.
  • Develop and perform onboarding and in-service presentations, both in person and virtually, with new and existing customer accounts.
  • Provide proactive customer education for prescribers, office staff, and imagers about the Pharmaceutical Diagnostic portfolio's payer coverage policies, reimbursement processes, patient services, and benefit investigation.
  • Serve as the primary point of contact for resolving general and patient-specific access and reimbursement challenges by leveraging required internal and external resources.
  • Develop access and reimbursement tools and guides and disseminate approved content related to product coverage, claims processing, prior authorizations, and appeals.
  • Maintain ongoing communication with Market Access Account Executives and Sales to provide field intelligence and prioritize key accounts regarding account interactions.
  • Attend conferences to promote GE HealthCare's Patient Support Services.
Desired Qualifications
  • Certified Professional Coding Certification.
  • Experience in radiopharmaceuticals, imaging, or diagnostics.
  • Product launch experience.
  • Living in Baltimore, Maryland, or Washington, District of Columbia, is preferred.

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Photonova Spectra won CE Mark on August 31, 2026, opening Europe sales.
  • Q2 2026 orders rose 11.1%, with 1.15x book-to-bill and record backlog.
  • Vivid cardiovascular ultrasound and ABUS breast screening launches broaden 2026 revenue opportunities.

What critics are saying

  • Patient Care Solutions revenue fell 13.5% in Q2 2026; management is reviewing a sale.
  • Jay Saccaro left in August 2026; William Grogan starts September 14, 2026.
  • If PCS recovery slips into 2027, GE HealthCare becomes a slower-growth imaging vendor.

What makes GE Healthcare unique

  • Photonova Spectra’s Deep Silicon CT differentiates GE HealthCare with photon-counting imaging.
  • GE HealthCare spans imaging, pharma diagnostics, ultrasound, and monitoring across hospital workflows.
  • The July 2026 backlog of $23.9 billion reflects sticky installed-base demand and services.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Relocation Assistance

Company News

Yahoo Finance
Sep 1st, 2026
GE HealthCare secures CE mark for Photonova Spectra photon-counting CT system

GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.

Yahoo Finance
Aug 31st, 2026
Vertex Pharmaceuticals shows promise while GE HealthCare and Wells Fargo face challenges

Vertex Pharmaceuticals has emerged as a standout S&P 500 stock, according to StockStory's analysis. The company, which focuses on developing transformative medicines for serious diseases including cystic fibrosis and sickle cell disease, boasts a market capitalisation of $137.3 billion. Meanwhile, StockStory recommends avoiding two large-cap stocks. GE HealthCare, spun off from General Electric in 2023, faces concerns over stagnant organic revenue growth and declining operating margins. The medical equipment provider has a market cap of $32.4 billion. Wells Fargo also made the avoid list. The diversified financial services company, with a $262.2 billion market cap, has seen its net interest margin shrink by 33.6 basis points over two years, suggesting increased competition or declining loan profitability.

Associated Press
Aug 28th, 2026
GE HealthCare launches three new Vivid cardiovascular ultrasound systems for diverse care settings

GE HealthCare has introduced three new cardiovascular ultrasound systems to its Vivid portfolio: Vivid Explorer 1, Vivid Advanced 1, and Vivid Focus 1. The systems were unveiled at the European Society of Cardiology Congress 2026 in Munich, Germany. Each system targets different clinical settings whilst sharing a common technology foundation with the ultra-premium Vivid Pioneer. Vivid Explorer is designed for high-volume echo labs, Vivid Advanced for mid-size hospitals and cardiology practices, and Vivid Focus for everyday cardiac imaging. All three systems use cSound imaging technology and include AI-enabled automation tools to streamline echo workflows. The systems have received CE Mark approval but are awaiting US FDA 510(k) clearance and are not yet available for sale in the United States.

Yahoo Finance
Aug 3rd, 2026
GE HealthCare launches Invenia ABUS Prime and StreamVue for breast cancer screening

GE HealthCare has launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio with solutions for supplemental screening in women with dense breasts. The Invenia ABUS Prime system has been installed at BeSound in Los Angeles, marking one of the first US installations. ABUS StreamVue is a browser-based reading solution enabling remote exam review across imaging networks. The system received FDA 510(k) clearance and CE Marking. Studies show 40% of women have dense breasts, carrying four to six times higher breast cancer risk. Research indicates mammography may miss one-third of cancers in dense breasts. Invenia ABUS Prime features AI-enabled tools including Scan Quality Assessment and can increase scan speed by up to 40%. The AI Assistant has demonstrated a 33% reduction in reading time.

Yahoo Finance
Jul 29th, 2026
GE HealthCare Q2: Orders up 11%, backlog hits record $23.9B amid Patient Care struggles

GE HealthCare Technologies reported second-quarter results with orders rising 11% year-over-year and backlog reaching a record $23.9 billion. Revenue grew 3.5% organically to $5.3 billion, driven by Advanced Imaging Solutions and Pharmaceutical Diagnostics, which posted organic growth of 5% and 14.6% respectively. Patient Care Solutions remained weak, with revenue falling 13.5% due to component shortages and fulfilment problems. Management is reviewing strategic options for the segment, including a potential sale. The company maintained its full-year outlook of 3–4% organic sales growth, adjusted earnings per share of $4.80–$5.00, and approximately $1.6 billion in free cash flow. CFO Jay Saccaro is departing, with George Newcomb serving as interim CFO.